 Royalty Pharma plc NASDAQ: RPRX has acquired Dicerna Pharmaceuticals Incs NASDAQ: DRNA royalty interest in Oxlumo lumasiran for an upfront cash payment of 180 million and up to 60 million in contingent sales-based milestone payments. The FDA and European Medicines Agency have approved Oxlumo EMA for the treatment of primary hyperoxaluria PH type 1 and is marketed by Alnylam Pharmaceuticals Inc NASDAQ: ALNY. 